|
|
|
|
|
|
|
|
|
|
|
|
Upcoming Meetings
|
|
|
|
|
Safety and Scientific Symposia |
|
|
|
|
Scientific Symposium - December 9-10, 2010
NIH RAC and CliniGene Scientific Symposium on "Retroviral and Lentiviral Vectors for Long-Term Gene Correction: Clinical Challenges in Vector and Trial Design"
|
|
|
|
|
Safety Symposium - June 15, 2010
Gene-Modified T Cells: Challenges in Clinical Trial Design
|
|
|
|
|
Safety Symposium on a Serious Adverse Event on OBA Protocol 705
|
|
|
|
|
Safety Symposium - March 15, 2005
Current Perspectives on Gene Transfer for X-SCID
|
|
|
|
|
Safety Symposium - September 21-22, 2004
Safety Considerations in Recombinant DNA Research with Pathogenic Viruses
|
|
|
|
|
Safety Symposium - March 7, 2001
Safety Considerations in the Use of AAV Vectors in Gene Transfer Clinical Trials
|
|
|
|
|
Safety Symposium - December 14, 2000
Safety Considerations in Cardiovascular Gene Transfer Clinical Research
|
|
|
|
|
Safety Symposium - March 8, 2000
Internally Deleted, Helper-Dependent Adenoviral Vectors
|
|
|
|
|
Biosafety Considerations for Research with Lentiviral Vectors |
|
|
|
|
Policy Conferences |
|
|
|
|
Gene Transfer and Rare Diseases Workshop (September 13, 2012)
|
|
|
|
|
RNA Oligonucleotides: Emerging Clinical Applications (December 15-16,2011)
|
|
|
|
|
Sham Neurological Procedures in Clinical Trials for Neurodegenerative Diseases: Scientific and Ethical Considerations (June 30, 2010 - July 1, 2010) |
|
|
|
|
NIH Public Consultation on Proposed Changes to the NIH Guidelines for Synthetic Nucleic Acids (June 23, 2009) |
|
|
|
|
Summaries and Reports of the Gene Therapy Policy Conferences (1998-Present)
|
|
|
|
|
IBCs in a Changing Research Landscape: A Policy Conference
|
|
|
|
|
Past Professional Development Conferences, Workshops, and Training Sessions |
|
|
|
|
Institutional Biosafety Committees: Promoting Optimal Practice Now and in the Future
|
|
|
|
|
The NIH System of Oversight of Human Gene Transfer Research: Optimizing Science, Safety and Ethics
|
|
|
|
|
IBC Basics: An Introduction to the NIH Guidelines and the Oversight of Recombinant DNA Research
|
|
|
|
|
The Future Face of IBCs: Evolving Roles and Responsibilities, Upcoming Challenges and Opportunities
|
|
|
|
|
|
Upcoming Meetings |
|
|
|
Events of Interest to IBCs and Others |
|
|
|
OBA will be participating in several key meetings in the next few months, sponsoring exhibits and training sessions that will offer information about the oversight of recombinant DNA research, as well as promote awareness about dual use life sciences research. Please take note of the following events: |
|
|
|
|
|
University of Minnesota - OBA will be conducting a full-day IBC training workshop on September 20, 2012, at the University of Minnesota. Further information can be found here. |
|
|
|
|
|
USDA - OBA will be participating in an IBC training event that will take place September 25-26, 2012, at the USDA/ARS National Animal Disease Center in Ames, IA. For further information contact Vicki Jones or call 515-337-7285 for registration information. |
|
|
|
|
|
Massachusetts Society for Medical Research - OBA staff will be presenting at the conference "IACUCs, IBCs & IRBs: Harmonization, Integration & Implementation", which will be held October 1-2, 2012, in Wellesley, MA. OBA staff will also be available during the conference to answer questions on the revised NIH Guidelines and dual use life science research oversight. Further information can be found at: Massachusetts Society for Medical Research. |
|
|
|
|
|
American Biological Safety Association - OBA will be conducting a half day pre-conference class, "Case Studies in Recombinant DNA and Dual Use Research of Concern" at the Annual ABSA Conference in Orlando, FL on October 20, 2012, from 8:00 am - 12:00 pm. OBA staff will also be available to answer questions at an exhibit booth during the conference. The exhibit will display educational material relating to the oversight of research involving recombinant DNA, as well as information on the oversight of dual use life science research. For more information about this event, visit: American Biological Association.
|
|
|
|
|
|
Policy Conference - September 13, 2012: |
|
|
|
Gene Transfer and Rare Diseases Workshop |
|
|
|
The NIH Office of Biotechnology Activities and Office of Rare Disease Research, NCATS, co-sponsored a workshop to discuss the advances in and challenges of gene transfer for rare diseases. There have been recent promising clinical successes in gene transfer protocols for rare diseases, such as retinal degeneration, hemophilia, and immune disorders. Investigators discussed their results to date and opportunities and challenges for extending these successes to other similar rare diseases. The panel discussions focused on strategies for maximizing opportunities for data sharing or platform development. |
|
|
|
|
Agenda (with links to briefings) |
|
|
|
|
Webcast |
|
Top of Page |
|
|
|
Policy Conference - December 15-16, 2011: |
|
|
|
RNA Oligonucleotides: Emerging Clinical Applications |
|
|
|
|
Agenda (with links to briefings) |
|
|
|
|
Webcast- December 15, 2011 - Day 1 |
|
|
|
|
Webcast- December 16, 2011 - Day 2 |
|
Top of Page |
|
|
|
Scientific Symposium - December 9-10, 2010: |
|
|
|
NIH RAC and CliniGene Scientific Symposium on "Retroviral and Lentiviral Vectors for Long-Term Gene Correction: Clinical Challenges in Vector and Trial Design"
|
|
|
|
|
Agenda (with links to briefings) |
|
|
|
|
Webcast- December 9, 2010 - Day 1 |
|
|
|
|
Webcast- December 10, 2010 - Day 2 |
|
Top of Page |
|
|
|
Safety Symposium - June 15, 2010: |
|
|
|
Gene-Modified T Cells: Challenges in Clinical Trial Design
|
|
|
|
|
Agenda |
|
|
|
|
Participant List |
|
|
|
|
Webcast |
|
|
|
|
RAC Points to Consider |
|
|
|
|
Meeting Publication: Cancer Research |
|
|
|
|
Reference Materials |
|
Top of Page |
|
|
|
Safety Symposium |
|
|
|
Safety Symposium on a Serious Adverse Event on OBA Protocol 705:
|
|
|
|
A Phase I/II Study of Repeat Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:FC Fusion Gene in Inflammatory Arthritis with and without Concurrent TNF-a Antagonist
|
|
|
|
|
Safety Symposium on a Serious Adverse Event on OBA Protocol 705 |
|
Top of Page |
|
|
|
Safety Symposium - March 15, 2005: |
|
|
|
Current Perspectives on Gene Transfer for X-SCID
|
|
|
|
|
Webcast - Morning session before break |
|
|
|
|
Webcast - Morning session after break |
|
|
|
|
Webcast - Afternoon session before break |
|
|
|
|
Webcast - Afternoon session after break |
|
|
|
|
Current Perspectives on Gene Transfer for X-linked Severe Combined Immunodeficiency Disease (X-SCID) |
|
Top of Page |
|
|
|
Safety Symposium - September 21-22, 2004: |
|
|
|
Safety Considerations in Recombinant DNA Research with Pathogenic Viruses
|
|
|
|
On September 21-22, 2004, NIH OBA held a safety symposium in conjunction with the meeting of the Recombinant DNA Advisory Committee (RAC). The symposium addressed safety considerations for recombinant DNA research with pathogenic viruses, focusing on containment issues for research with such viruses as 1918 influenza virus, highly pathogenic avian influenza viruses, and SARS Co-V. A major goal of the symposium was to develop a Points to Consider document and other resources to assist IBCs in conducting risk assessments and determining appropriate containment.
|
|
|
|
|
Agenda and Participant List |
|
|
|
|
Webcast - Day one - Morning session before break |
|
|
|
|
Webcast - Day one - Morning session after break |
|
|
|
|
Webcast - Day one - Afternoon session before break |
|
|
|
|
Webcast - Day one - Afternoon session after break |
|
|
|
|
Reference Information |
|
|
|
|
Frequently Asked Questions - Risk Assessment and Determining Containment |
|
Top of Page |
|
|
|
Safety Symposium - March 7, 2001: |
|
|
|
Safety Considerations in the Use of AAV Vectors in Gene Transfer Clinical Trials
|
|
|
|
|
Transcript |
|
Top of Page |
|
|
|
Safety Symposium - December 14, 2000: |
|
|
|
Safety Considerations in Cardiovascular Gene Transfer Clinical Research
|
|
|
|
|
Transcript |
|
Top of Page |
|
|
|
Safety Symposium - March 8, 2000: |
|
|
|
Internally Deleted, Helper-Dependent Adenoviral Vectors
|
|
|
|
|
Transcript |
|
|
|
|
Summary |
|
Top of Page |
|
|
|
Summaries and Reports of the Gene Therapy Policy Conferences (1998-Present) |
|
|
|
Prenatal Gene Therapy: Scientific, Medical, & Ethical Issues - January 7-8, 1999 |
|
|
|
|
Full Report |
|
|
|
|
Summary |
|
|
|
|
RAC Statement Regarding In Utero Gene Transfer Research |
|
|
|
Lentiviral Vectors for Gene Delivery - March 9, 1998 |
|
|
|
|
Summary |
|
|
|
|
Preclinical Safety Evaluation of Lentivirus Vectors: FDA Regulatory Expectations - Anne M. Pilaro, Ph.D. |
|
Top of Page |
|
|
|
"IBCs in a Changing Research Landscape: A Policy Conference" |
|
|
|
Bethesda, Marriott, December 7-8, 2001 |
|
|
|
|
Conference Summary |
|
|
|
|
Webcasts Day 1 |
|
|
|
|
Welcome |
|
|
|
|
Session 1 |
|
|
|
|
Session 2 |
|
|
|
|
Session 3 |
|
|
|
|
Session 4 |
|
|
|
|
Webcasts Day 2 |
|
|
|
|
Morning Session |
|
|
|
|
Afternoon Session |
|